5732-88-7

Usage

Uses

Used in Pharmaceutical Synthesis:
Cyclopentylideneacetonitrile serves as an intermediate in the production of pharmaceuticals, contributing to the development of medications that address a range of health conditions.
Used in Agrochemical Production:
cyclopentylideneacetonitrile is also utilized as an intermediate in the synthesis of agrochemicals, playing a part in creating substances that help protect and enhance crop yields.
Used in Organic Chemistry:
Cyclopentylideneacetonitrile holds potential applications in the field of organic chemistry, where it can be employed as a starting material for the synthesis of other organic compounds.
Used as a Building Block for New Molecules:
It can be used as a building block for the development of new molecules with specific properties and functions, thereby contributing to the advancement of chemical research and innovation.
Safety Note:
Due to its hazardous nature, cyclopentylideneacetonitrile can cause skin and eye irritation. It is crucial to handle and store it with care, using appropriate personal protective equipment and ensuring the work area is well-ventilated.

InChI:InChI=1/C7H9N/c8-6-5-7-3-1-2-4-7/h5H,1-4H2

Upstream product

• 5623-84-7 cyclopentyliden-acetic acid amide 
• 120-92-3 cyclopentanone 
• 30963-90-7 cyclopentylidenemalononitrile 
• 104413-32-3 7-bromo-2-heptenenitrile 
• 2537-48-6 diethyl 1-cyanomethylphosphonate 
• 75-77-4 chloro-trimethyl-silane 
• 18881-60-2 bis-trimethylsilanyl-acetonitrile 
• 59463-54-6 S-cyanomethyl O-ethyl carbonodithioate 
• 63846-68-4 Cyclopentyl-(2-nitro-phenylselanyl)-acetonitrile 
• 22734-04-9 cyclopent-1-enyl-acetonitrile 
• 141-52-6 sodium ethanolate 
• 107-14-2 chloroacetonitrile 

Downstream Products

• 120-92-3 cyclopentanone 
• 127914-49-2 1-Cyclopentylidenebut-3-yn-2-yl benzoate 
• 753023-64-2 (1-Aminocyclopentyl)acetonitrile 
• 5662-93-1 (2E)-4-cyclopentylidenebut-2-enoic acid 
• 5732-87-6 2-cyclopentylacetonitrile 
• 22734-04-9 cyclopent-1-enyl-acetonitrile 

Relevant academic research and scientific papers

Overcoming Selectivity Issues in Reversible Catalysis: A Transfer Hydrocyanation Exhibiting High Kinetic Control

Reversible catalytic reactions operate under thermodynamic control, and thus, establishing a selective catalytic system poses a considerable challenge. Herein, we report a reversible transfer hydrocyanation protocol that exhibits high selectivity for the thermodynamically less favorable branched isomer. Selectivity is achieved by exploiting the lower barrier for C-CN oxidative addition and reductive elimination at benzylic positions in the absence of a cocatalytic Lewis acid. Through the design of a novel type of HCN donor, a practical, branched-selective, HCN-free transfer hydrocyanation was realized. The synthetically useful resolution of a mixture of branched and linear nitrile isomers was also demonstrated to underline the value of reversible and selective transfer reactions. In a broader context, this work demonstrates that high kinetic selectivity can be achieved in reversible transfer reactions, thus opening new horizons for their synthetic applications.

Rhodium-Catalyzed 1,1-Hydroacylation of Thioacyl Carbenes with Alkynyl Aldehydes and Subsequent Cyclization

A rhodium-catalyzed 1,1-hydroacylation of thioacyl carbenes with alkynyl and alkenyl aldehydes and subsequent 6-endo-trig/dig cyclization are realized, giving structurally diverse 4H-thiopyran-4-ones and 2,3-dihydro-4H-thiopyran-4-ones in moderate to good yields. The oxidative addition of Rh(I) to aldehydes is proposed to be the turnover-limiting step. Manipulations of estrones demonstrate the applications of our formal (3 + 3) transannulations in the structural modifications of natural products.

PROTEIN KINASE INHIBITORS

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec or Src protein kinase families. The present invention also relates to the processes of preparation of these compounds, their intermediates, to the pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, autoimmune, or infectious disease, disorders, or conditions in which protein kinase activity is implicated. More particularly, the present invention relates to a compound of Formula I.

Organocatalytic, Asymmetric Eliminative [4+2] Cycloaddition of Allylidene Malononitriles with Enals: Rapid Entry to Cyclohexadiene-Embedding Linear and Angular Polycycles

A direct aminocatalytic synthesis has been developed for the chemo-, regio-, diastereo-, and enantioselective construction of densely substituted polycyclic carbaldehydes containing fused cyclohexadiene rings. The chemistry utilizes, for the first time, remotely enolizable π-extended allylidenemalononitriles as electron-rich 1,3-diene precursors in a direct eliminative [4+2] cycloaddition with both aromatic and aliphatic α,β-unsaturated aldehydes. The generality of the process is demonstrated by approaching 6,6-, 5,6-, 7,6-, 6,6,6-, and 6,5,6-fused ring systems, as well as biorelevant steroid-like 6,6,6,6,5- and 6,6,6,5,6-rings. A stepwise reaction mechanism for the key [4+2] addition is proposed as a domino bis-vinylogous Michael/Michael/retro-Michael reaction cascade. The utility of the malononitrile moiety as traceless activating group of the dicyano nucleophilic substrates is demonstrated.

GEMINALLY SUBSTITUTED CYANOETHYLPYRAZOLO PYRIDONES AS JANUS KINASE INHIBITORS

The instant invention provides compounds of Formula (I) which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.

3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors

New pyridazin-3(2H)-one derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of the phosphodiesterase IV (PDE4).

HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).

5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES

Compounds of Formula I: (Formula should be inserted here) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1, R2, R3, R4, R5, R6, R7, X1 and X2 have the meanings given in the specification, are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases, inflammatory diseases, rejection of transplanted organs, tissues and cells, as well as hematologic disorders and malignancies and their co-morbidities.

PYRROLOPYRAZINE DERIVATIVES AS SYK AND JAK INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula (I), wherein the variables Q and R1 and R2 are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

4, 6-DISUBSTITUTED 2-AMINO-PYRIMIDINES AS HISTAMINE H4 RECEPTOR MODULATORS

The present invention relates to substituted heterocyclic compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors/antagonists useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.